Last updated: July 31, 2026
Phendimetrazine tartrate is an established, low-cost sympathomimetic anorectic with limited patent protection and substantial generic competition. Commercial opportunity is concentrated in differentiated oral formulations, excipient-controlled performance, supply reliability, and lifecycle management rather than in new chemical-entity exclusivity. The strongest formulation concepts are abuse-mitigation, improved swallowability, reduced gastrointestinal variability, and controlled-release products that can satisfy FDA requirements for a new drug application or 505(b)(2) pathway.
What is the FDA status of phendimetrazine tartrate?
Phendimetrazine tartrate is approved as a short-term adjunct to caloric restriction for the management of exogenous obesity. It is a sympathomimetic amine pharmacologically related to amphetamines and is classified as a Schedule III controlled substance in the United States (DailyMed, 2024a).
The marketed dosage forms include:
| Dosage form |
Common strength |
Typical dosing position |
Commercial status |
| Immediate-release tablet |
35 mg |
Usually administered before meals |
Generic and branded products |
| Extended-release capsule |
105 mg |
Typically administered once in the morning |
Limited branded and generic availability |
| Tartrate API |
N/A |
Active pharmaceutical ingredient |
Controlled-substance supply chain |
The approved labeling limits treatment to short-term use. Chronic obesity therapy, broad cardiometabolic indications, and combination use with other weight-loss agents are not established commercial extensions under the existing label (DailyMed, 2024a).
What patents protect phendimetrazine tartrate?
Phendimetrazine tartrate has little apparent active-patent protection relevant to ordinary generic tablets. The drug was approved decades ago, and its core composition and conventional oral dosage forms are exposed to generic competition.
The relevant intellectual-property position is best summarized as follows:
| IP category |
Current commercial relevance |
| Compound patent |
No meaningful current exclusivity for the established active ingredient |
| Conventional 35 mg tablet |
Generally exposed to generic competition |
| 105 mg extended-release capsule |
Product-specific formulation protection may be possible, but broad blocking protection is not apparent from the legacy product history |
| Method-of-use patents |
Limited relevance because the approved use is an old, short-term obesity indication |
| Excipient or delivery patents |
Potentially valuable for new controlled-release, abuse-deterrent, taste-masked, or patient-adherence products |
| Manufacturing patents |
Potentially useful for differentiated release profiles, impurity control, or controlled-substance handling |
The FDA Orange Book should be checked for current listed patents and regulatory exclusivities for each marketed reference product. For an old drug such as phendimetrazine tartrate, the principal competitive barriers are usually FDA approval, bioequivalence, controlled-substance compliance, manufacturing capacity, and distribution economics rather than Orange Book exclusivity (FDA, 2024a).
When does phendimetrazine tartrate lose exclusivity?
Phendimetrazine tartrate has already lost practical market exclusivity. Generic products are available, and conventional dosage forms are not protected by a current new chemical entity exclusivity period.
The commercial timeline is:
| Milestone |
Position |
| Original approval |
Historical approval; the product is no longer within NCE exclusivity |
| Conventional generic entry |
Established |
| Orange Book patent cliff |
No major current cliff expected for the legacy active ingredient |
| Regulatory exclusivity |
No meaningful current exclusivity expected for ordinary tablets |
| Future exclusivity |
Available only through a qualifying new formulation, new indication, or other statutory pathway |
A reformulated product could obtain FDA regulatory exclusivity if it meets the requirements for a new drug application. The protection would attach to the qualifying product and approved claims, not to phendimetrazine tartrate generally.
What excipients are used in phendimetrazine tartrate tablets and capsules?
Inactive ingredients vary by manufacturer, dosage form, and release design. Representative immediate-release tablets commonly use excipients drawn from the following functional groups:
| Excipient class |
Typical examples |
Primary function |
| Diluent |
Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate |
Tablet mass and compressibility |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Granule and tablet strength |
| Disintegrant |
Sodium starch glycolate, crospovidone, croscarmellose sodium |
Rapid tablet breakup |
| Glidant |
Colloidal silicon dioxide |
Powder flow |
| Lubricant |
Magnesium stearate, stearic acid |
Ejection and tooling control |
| Opacifier or colorant |
Titanium dioxide, iron oxides, approved dyes |
Product identification |
| Capsule shell |
Gelatin or hypromellose |
Encapsulation and product presentation |
These ingredients are not interchangeable from a regulatory perspective. A change in lactose level, lubricant concentration, disintegrant grade, or granulation process can alter dissolution, tablet robustness, content uniformity, and bioequivalence performance.
The 105 mg extended-release dosage form requires a more complex excipient system. Potential technologies include:
- Hydrophilic matrix polymers such as hydroxypropyl methylcellulose.
- Hydrophobic matrix materials such as ethylcellulose or fatty acid derivatives.
- Multiparticulate pellets coated with polymeric release membranes.
- Ion-exchange resin complexes.
- Osmotic or diffusion-controlled systems.
- Capsule-in-capsule or coated-bead architectures.
A formulation developer should not assume that the 35 mg immediate-release tablet can be scaled directly to a 105 mg once-daily product. The dose, release profile, pharmacokinetic exposure, and controlled-substance risk profile are different.
How can excipients improve the commercial value of phendimetrazine tartrate?
The most practical excipient opportunities are tied to measurable product attributes.
Improving dose uniformity
Phendimetrazine tartrate is a relatively low-dose active in the 35 mg tablet. Low-dose formulation creates risks involving segregation, blend uniformity, and content uniformity. Direct compression may be suitable if particle-size distribution and flow are controlled. Wet or dry granulation may provide better uniformity when the API has poor flow or poor compactibility.
A robust strategy may use:
- Microcrystalline cellulose for compressibility.
- Colloidal silicon dioxide for flow improvement.
- A low-level binder for granule strength.
- A fast-acting superdisintegrant for prompt release.
- Tight control of magnesium stearate mixing time to avoid dissolution suppression.
The commercial value is operational. A formulation with consistent content uniformity and low tablet-failure rates can reduce batch rejection and support dependable generic supply.
Improving dissolution and gastrointestinal consistency
The tartrate salt may exhibit formulation-dependent dissolution behavior. Developers can manage this through API particle-size control, wetting agents, disintegrant selection, and granulation conditions.
Potential approaches include:
- Crospovidone for rapid capillary water uptake.
- Croscarmellose sodium for swelling-driven breakup.
- Low-level surfactants where justified by dissolution data.
- Spray-dried or co-processed excipients for improved powder performance.
- Solid-dispersion approaches if dissolution is limited by API properties.
The formulation objective should be rapid and reproducible release for immediate-release tablets, not simply rapid disintegration. Dissolution testing remains the more commercially relevant performance measure.
Supporting extended release
A once-daily extended-release product could offer a stronger commercial position than another 35 mg immediate-release tablet. The formulation must reproduce a clinically acceptable exposure profile while avoiding dose dumping.
Potential excipient platforms include:
| Platform |
Commercial advantage |
Main development risk |
| Hydrophilic HPMC matrix |
Low manufacturing complexity and broad excipient availability |
Food effects, alcohol sensitivity, and release variability |
| Coated pellets |
Flexible release engineering and capsule presentation |
More complex coating process and higher cost |
| Ethylcellulose matrix |
Durable diffusion control |
Potentially incomplete release or high process sensitivity |
| Osmotic system |
Strong control of release rate |
Higher development cost and more complex manufacturing |
| Ion-exchange resin |
Can support sustained release and taste masking |
Resin loading limits and regulatory characterization |
The 105 mg extended-release product is the most credible platform for lifecycle differentiation, but it also has the highest development and bioequivalence burden.
What formulation patents could protect a new phendimetrazine product?
A new patent estate would need to claim a specific technical solution rather than the active ingredient alone. Potential claim categories include:
- A defined extended-release profile measured by dissolution at multiple time points.
- A multiparticulate dosage form with specified polymer coating levels.
- A controlled-release matrix containing defined ratios of hydrophilic and hydrophobic polymers.
- A formulation with reduced alcohol-induced dose dumping.
- A tamper-resistant tablet that limits extraction or rapid release.
- A formulation with improved stability under high humidity.
- A low-dose blend with specified content-uniformity performance.
- A manufacturing process that controls a critical impurity or degradation pathway.
- A pediatric or geriatric dosage form with improved swallowability.
- A fixed-dose or combination product, if separately supported by clinical and regulatory evidence.
Patent strength would depend on whether the claims cover a real design space or only a narrow example. A claim directed to a precise polymer ratio may be easier to design around than a claim linked to a distinctive release profile, robust abuse-deterrence mechanism, and clinically relevant performance.
What abuse-deterrent excipient opportunities exist?
Phendimetrazine is a controlled substance with stimulant-related abuse concerns. Abuse-deterrent design could therefore support a differentiated product, but it would not automatically create an FDA-recognized abuse-deterrent claim.
Potential technologies include:
- High-molecular-weight polymers that form a viscous gel when crushed and exposed to water.
- Matrix systems that resist milling and rapid extraction.
- Ion-exchange complexes that reduce immediate release after manipulation.
- Physical barriers that make crushing and solvent extraction more difficult.
- Combination of a release-control polymer with an aversive or sequestering component.
A developer would need to distinguish between formulation resistance and FDA labeling claims. FDA guidance requires laboratory, pharmacokinetic, and potentially postmarket evidence before abuse-deterrent labeling can be supported (FDA, 2015).
The commercial case is strongest if the product can demonstrate abuse-mitigation performance without materially increasing tablet size, swallowing difficulty, manufacturing cost, or release variability.
What generic entry risks exist for phendimetrazine tartrate?
Generic entry risk is high for conventional immediate-release tablets. The market has low technical complexity, established manufacturing knowledge, and limited patent protection.
Risk is lower for a technically differentiated extended-release or abuse-deterrent formulation because competitors would need to address:
- Formulation-specific bioequivalence.
- Release-profile matching.
- Dose-dumping studies.
- Controlled-substance registration and security controls.
- Specialized coating or multiparticulate equipment.
- Stability and extractables data.
- Potentially more complex ANDA or 505(b)(2) regulatory requirements.
A conventional 35 mg tablet is therefore a volume and supply-chain business. A differentiated 105 mg product is a formulation and regulatory business.
Which companies are positioned to compete?
Competition is divided among three groups:
| Competitor group |
Product strategy |
Competitive pressure |
| Legacy brand owners |
Branded immediate-release or extended-release products |
Brand recognition, but limited pricing power |
| Generic manufacturers |
Conventional 35 mg tablets and established capsules |
High price pressure and substitution |
| Specialty developers |
Reformulated controlled-release or abuse-mitigation products |
Lower direct competition but higher development cost |
The most defensible opportunity is not another undifferentiated tablet. It is a product with a clear prescriber or payer value proposition, such as once-daily dosing, improved supply reliability, lower excipient allergen burden, or a validated abuse-mitigation profile.
What is the Orange Book status of phendimetrazine tartrate?
The Orange Book remains the primary FDA source for listed patents, therapeutic equivalence evaluations, and reference-product information. The relevant review should cover each strength and dosage form separately because a patent or exclusivity listing may apply to a specific product rather than the active ingredient as a whole (FDA, 2024a).
For phendimetrazine tartrate, the expected strategic position is:
- Ordinary immediate-release tablets: high substitution risk.
- Extended-release capsules: potentially more differentiated, but still exposed to generic competition where approved equivalents exist.
- New formulation: possible patent and regulatory-exclusivity opportunity if supported by a new drug application.
- Method-of-use protection: limited unless a new clinical use is developed and approved.
What regulatory pathway applies to a new excipient-based product?
A conventional generic that matches the reference product can generally pursue an abbreviated new drug application. A product with a materially different release system, new abuse-deterrent properties, or a new route may require a 505(b)(2) application rather than a standard ANDA.
The pathway depends on the product’s differences:
| Product change |
Likely regulatory issue |
| Different color, filler, or lubricant with equivalent performance |
ANDA formulation and bioequivalence requirements |
| New extended-release mechanism |
May require complex ANDA or 505(b)(2) strategy |
| Abuse-deterrent formulation |
Additional abuse-potential studies and labeling analysis |
| New dosage form or route |
Likely 505(b)(2) or full NDA requirements |
| New obesity indication or chronic-use claim |
Clinical evidence and labeling expansion |
| New excipient with limited oral precedent |
Toxicology and safety justification |
FDA’s Inactive Ingredient Database can support excipient selection by showing prior use in approved products, route, dosage form, and concentration context (FDA, 2024b). Prior use does not eliminate the need to justify the proposed level and formulation role.
How does phendimetrazine compare with newer obesity drugs?
Phendimetrazine competes poorly on long-term weight-management efficacy, chronic-use positioning, and cardiometabolic evidence. Newer glucagon-like peptide-1 products and dual incretin therapies have stronger clinical and commercial momentum but are more expensive and often constrained by supply, injection requirements, or payer controls.
Phendimetrazine retains potential advantages in:
- Low acquisition cost.
- Oral administration.
- Familiar generic distribution.
- Simple immediate-release manufacturing.
- Use in selected short-term treatment settings.
Its disadvantages include controlled-substance restrictions, stimulant-related safety concerns, short-term labeling, and limited opportunity for premium pricing.
An excipient-led product must therefore improve convenience or risk management. Excipients alone will not overcome the limitations of the active ingredient’s label or pharmacology.
What licensing and partnership opportunities exist?
Licensing value is most likely to arise from formulation technology rather than from the phendimetrazine molecule. Potential deal structures include:
- Licensing a controlled-release platform to a generic manufacturer.
- Supplying coated pellets or polymeric matrices under a technology-transfer agreement.
- Co-developing an abuse-deterrent product with a specialty pharmaceutical company.
- Contract manufacturing of controlled-substance tablets under a quality and security agreement.
- Acquiring a dormant formulation asset with historical regulatory data.
A commercial agreement should allocate responsibility for DEA compliance, API sourcing, batch-release testing, pharmacovigilance, recalls, patent prosecution, and Paragraph IV litigation.
What litigation and Paragraph IV risks affect the market?
Conventional phendimetrazine products face limited apparent litigation exposure because the principal market is already genericized. Future litigation risk would increase if a new extended-release or abuse-deterrent product obtains Orange Book-listed patents.
A generic challenger could raise Paragraph IV certifications against listed patents. The commercial consequences would depend on:
- Whether the patent claims the product, formulation, or method of use.
- Whether the patent is listed for the relevant strength and dosage form.
- Whether a 30-month stay is triggered.
- Whether the innovator has a settlement agreement.
- Whether the challenger has a noninfringement or invalidity position.
- Whether an authorized generic is launched.
No current high-value settlement pattern is central to the legacy phendimetrazine market. The principal litigation risk would arise from a new branded formulation, not from the old immediate-release tablet.
What is the revenue exposure and commercial outlook?
Revenue potential for an undifferentiated generic tablet is constrained by low pricing and multiple suppliers. A product with reliable supply, fewer manufacturing failures, and a differentiated dosage schedule could capture value despite the small overall market.
The strongest opportunities are:
- A once-daily extended-release capsule with reproducible pharmacokinetics.
- A smaller, easier-to-swallow tablet for patients who have difficulty with conventional dosage forms.
- A low-allergen formulation that avoids selected excipient concerns.
- A humidity-stable product suitable for broad distribution.
- A controlled-release product with laboratory-supported tamper resistance.
- A dual-source API and excipient supply chain that reduces shortage exposure.
The weakest opportunity is a simple reformulation with no clinically meaningful performance advantage and no credible patent position.
Key Takeaways
- Phendimetrazine tartrate is an old, genericized controlled substance with limited current exclusivity.
- Conventional 35 mg immediate-release tablets are exposed to strong price and substitution pressure.
- The main formulation opportunity is a differentiated 105 mg extended-release or abuse-mitigation product.
- Excipients can improve content uniformity, dissolution, stability, swallowability, and release control.
- A new formulation patent must claim a specific technical architecture or measurable performance profile.
- FDA regulatory status depends on whether the product is an equivalent generic or a materially different formulation.
- Licensing value is concentrated in delivery technology, manufacturing capability, and controlled-substance compliance.
- Generic entry risk is high for standard tablets and lower for technically complex extended-release products.
- The commercial ceiling remains limited by short-term labeling, stimulant safety concerns, and competition from newer obesity therapies.
FAQs About Phendimetrazine Tartrate Excipients and Commercialization
Can lactose-free phendimetrazine tartrate tablets be commercialized?
Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler, provided the product meets manufacturing, stability, dissolution, and bioequivalence requirements.
Can phendimetrazine tartrate be formulated as an orally disintegrating tablet?
Yes, but taste masking, dose uniformity, tablet friability, and controlled-substance handling require specific development work. A fast-disintegrating product could support geriatric or dysphagic populations, but it may also increase misuse concerns if rapid drug release is not controlled.
Is an extended-release phendimetrazine product commercially attractive?
It can be attractive if it provides a meaningful once-daily benefit and achieves a defensible release profile. The product would face greater bioequivalence, stability, manufacturing, and dose-dumping requirements than a conventional tablet.
Can an excipient create FDA exclusivity by itself?
No. FDA exclusivity generally depends on the qualifying application, clinical development, new dosage form, new indication, or statutory category. An excipient change may support a patent or a new formulation, but it does not independently create exclusivity.
Are phendimetrazine tartrate products subject to biosimilar competition?
No. Phendimetrazine tartrate is a small-molecule drug, not a biologic. Competition occurs through generic drug pathways, including ANDAs, rather than biosimilar applications.
References
-
DailyMed. (2024a). Phendimetrazine tartrate tablet: Prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. U.S. Department of Health and Human Services. https://www.fda.gov/
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Food and Drug Administration. (2024b). Inactive Ingredient Database. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/iig/
